Biomerica, Inc. — Form 10-Q Summary
Reporting period: Fiscal third quarter and nine months ended February 29, 2024; filed April 12, 2024. Comparisons are to the three and nine months ended February 28, 2023. Biomerica develops and sells diagnostic products, with a strategic focus on its inFoods IBS test and other gastrointestinal products.
Financial results
| Metric | Three months ended February 29, 2024 | Nine months ended February 29, 2024 |
|---|---|---|
| Revenue | $1.017 million, down 8% year over year | $4.299 million, up 2% |
| Gross profit (loss) and margin | $(149,000); approximately -14.7% | $591,000; approximately 13.7% |
| Operating expenses | $1.851 million | $5.430 million |
| Operating loss | $(2.000) million | $(4.839) million |
| Net loss | $(1.918) million; $(0.11) per share | $(4.557) million; $(0.27) per share |
| Cash used in operating activities | Not reported for the quarter | $(4.317) million |
At February 29, 2024, cash and cash equivalents were $5.319 million, working capital was $6.855 million, and total liabilities were $2.534 million. Liabilities include $862,000 of operating lease obligations; the filing reports no conventional borrowings. Cash declined $4.400 million from May 31, 2023. Nine-month investing cash outflow was $91,000, and financing cash flow was zero. Management says available cash and the ability to raise equity are expected to fund operations through at least May 2025.
Changes versus comparable periods
- Quarterly revenue fell $94,000, primarily due to lower food-intolerance product sales; quarterly cost of sales rose 18% to $1.166 million, chiefly attributed to international shipping logistics. The quarter therefore shifted from gross profit of $120,000 to a gross loss of $149,000.
- Nine-month revenue increased $68,000 despite no COVID-19 product sales in the period. Clinical laboratory, OTC, and contract-manufacturing sales rose, while physician’s-office sales fell from $249,000 to $8,000.
- Nine-month gross profit improved to $591,000 from $417,000, with cost of sales declining to 86% of revenue from 90%. Operating loss narrowed to $4.839 million from $5.387 million, and net loss improved to $4.557 million from $5.348 million.
- Nine-month SG&A declined 8%, mainly reflecting lower legal and share-based compensation costs, partly offset by sales-team and marketing investment. R&D was approximately flat at $1.226 million. Higher interest income contributed to the improved nine-month net loss.
Business outlook, risks, and notable items
- Management anticipates continued inFoods IBS revenue growth in coming quarters. The company reports rollout to multiple GI physician groups, ongoing discussions with potential partners, and work to improve ordering and testing processes.
- The FDA cleared hp+detect, the company’s H. pylori diagnostic test, on December 18, 2023. Biomerica began marketing it to U.S. laboratories and expects a favorable revenue trajectory during 2024; international distributor discussions are also underway. These are management expectations, not guaranteed results.
- The company has not set a date for a possible pivotal inFoods IBS trial. It is also evaluating another disease indication for the inFoods platform.
- Liquidity remains a key consideration: the company has continuing losses, negative operating cash flow, and an accumulated deficit of $46.774 million. Management’s runway estimate depends in part on its ability to raise additional funds; a new shelf registration permits up to $20 million of equity sales through September 2026.
- Customer and supplier concentration is notable: one customer represented 40% of nine-month revenue; three customers represented 44% of quarterly revenue and gross receivables. One vendor represented 50% of quarterly raw-material purchases, and two vendors represented 52% of accounts payable.
- Management cites international shipping and logistics, supply-chain disruptions, cost inflation, geopolitical tensions, and general economic conditions as risks. No material legal proceedings or subsequent events were reported. Management concluded disclosure controls were effective at the reasonable-assurance level.
Important facts for investors to verify
- Whether inFoods IBS adoption and hp+detect commercialization generate meaningful recurring sales, and whether management’s growth expectations are realized.
- Whether gross margins recover after the quarterly gross loss and elevated shipping costs.
- Cash burn, remaining runway, and any need for additional financing; potential dilution from equity issuance and outstanding options (3,506,616 at February 29, 2024).
- Customer and supplier concentration, receivable collections, and international logistics exposure.
- The status and timing of any pivotal inFoods IBS trial and regulatory plans for future products.